NCT04781426

PrEP Among MSM and TG in Myanmar

Pre-exposure Prophylaxis of HIV Infection Among Men Who Have Sex With Men (MSM) and Transgender Women (TG) in Suburban Yangon, Myanmar

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 200 (actual)
• Sponsor: Myanmar Oxford Clinical Research Unit · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

HIV is concentrated among key populations in Myanmar. Globally, HIV-prevalence among transgender (TG) women is one of the highest; laboratory-confirmed prevalence is reported up to 40%. In September 2015, WHO recommended the use of Pre-Exposure Prophylaxis (PrEP) for people at substantial risk of HIV as part of a combination HIV prevention strategy. A demonstration project will take place to implement and evaluate the uptake and effectiveness of PrEP among MSM, and TG women in a clinic in Hlaingtharyar township, Yangon. The aim is to describe PrEP uptake, as well as HIV-seroconversion and STI infection rates among those who use PrEP.

Conditions

• HIV Infections

Interventions

Type	Name	Description
DRUG	Tenofovir Disoproxil Fumarate (TDF) 300 mg	PrEP regimens of Tenofovir Disoproxil Fumarate (TDF) 300 mg/Lamivudine (3TC) 300mg per oral (PO) daily

Timeline

• Start date: 2020-10-28
• Primary completion: 2021-08-31
• Completion: 2021-08-31
• First posted: 2021-03-04
• Last updated: 2022-03-11

Locations

1 site across 1 country: Burma